MODEL VERDICT
Cytokinetics, Incorporated (CYTK)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Each row records the model's monthly assessment. High Conviction = the model detected notable undervaluation vs peers. Neutral = no notable divergence was found. The return column shows the actual price change over 90 days for reference. This is a quantitative observation log — not investment advice.
| Date | Assessment | Score | Price | Status | 90d Fwd Return |
|---|---|---|---|---|---|
| May 1, 2026 | NEUTRAL | 0.14 | $63.35 | CURRENT | — |
| Apr 24, 2026 | NEUTRAL | 0.14 | $65.32 | CURRENT | — |
| Apr 17, 2026 | NEUTRAL | 0.14 | $66.71 | CURRENT | — |
| Apr 16, 2026 | NEUTRAL | 0.14 | $65.37 | CURRENT | — |
| Apr 10, 2026 | NEUTRAL | 0.14 | $65.01 | CURRENT | — |
Historical model observations for research purposes only. Past quantitative patterns do not predict future results. Not a recommendation to buy, sell, or hold any security.
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| EV To Revenue 8 industry peers | $3.29 | -94.8% | 4% | B | Data |
| Price / Sales 8 industry peers | $6.72 | -89.4% | 3% | B | Model Driven |
| Weighted Output Blended model output | $46.64 | -26.4% | 100% | 58 | OVERVALUED |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/S Ratio | 226.01 | 49.76 | 22.74 | 1070.22 | 383.43 |
Based on our peer multiples analysis with 5 valuation metrics, the model estimates CYTK's fair value at $46.64 vs the current price of $63.35, implying -26.4% downside potential. Model verdict: Overvalued. Confidence: 58/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $46.64 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%). Monte Carlo simulation (10,000 iterations) gives a range of $3.05 (P10) to $102.90 (P90), with a median of $33.87.
CYTK's current P/E of -9.7x compares to the industry median of 34.5x (3 peers in the group). This represents a -128.1% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
34 analysts cover CYTK with a consensus rating of Buy. The consensus price target is $92.50 (range: $69.00 — $136.00), implying +46.0% upside from the current price. Grade breakdown: Strong Buy (0), Buy (32), Hold (2), Sell (0), Strong Sell (0).
The model confidence score is 58/100, based on: data completeness (6), peer quality (25), historical depth (20), earnings stability (5), and model agreement (2). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for CYTK.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.